Glabellar Lines
AI-09 injectable improves frown lines up to 6 months
The ready-to-use liquid injectable neuromodulator AI-09 achieved successful results in a phase 1-2 study for the treatment of moderate to severe glabellar wrinkles, Eirion Therapeutics Inc. announced in a press release.
RelabotulinumtoxinA demonstrates rapid onset, durability for frown lines, crow’s feet
New, topline results from two phase 3b trials showed relabotulinumtoxinA has a rapid onset of action and durability for the treatment of glabellar and canthal lines, Galderma announced in a press release.
Increased dose of Jeuveau corrects glabellar lines up to 6 months
CHICAGO — A 40-unit formulation of Jeuveau achieved positive outcomes for the treatment of glabellar lines in adults for up to 6 months, Evolus announced in a press release.
FDA approves Daxxify for glabellar line improvement
The FDA has approved the neuromodulator injection Daxxify for the temporary improvement of moderate to severe glabellar lines, Revance Therapeutics Inc. announced in a press release.
FDA approves BLA resubmission for daxibotulinumtoxinA injection
Increased incobotulinumtoxinA doses prolong frown line reduction
IncobotulinumtoxinA was effective and safe in the reduction of glabellar frown lines at multiple dose levels, with higher doses achieving prolonged results, according to phase 2 study results.